Local websites
Businesses
Other websites
General contact

Head Office
Novartis International AG
CH-4002 Basel
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 - 17:00, GMT+1
(Central European Time)

More information

Investors

Novartis International AG
Investor Relations
P.O. Box
CH-4002 Basel
Switzerland

+41 61 324 79 44

More information

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

More information

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

 

Drug discovery and development process

Novartis drug discovery and development efforts begin and end with the patient. Our R&D efforts are guided by two principles:

  • Do we understand the underlying mechanism or cause of the disease?
  • Does this disease represent a significant unmet medical need in patients?

If the answer to both questions is "yes," then we develop a research program aimed at better understanding the disease and finding an effective chemical or biologic based medicine.

Drug discovery and development process Drug discovery and development process

Back to top

Top links
Top downloads
Annual report 2012

Annual report 2012 >